{"product_id":"veracyte-ansoff-matrix","title":"Veracyte Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Veracyte Ansoff Matrix Analysis gives you a clear, company-specific view of the company's growth options across market penetration, market development, product development, and diversification. The page already shows a real preview of the analysis, so you can review the actual content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDriving high-risk prostate cancer dominance with 65 percent market share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte is pushing Decipher Prostate deeper into high-risk urology care, where it now holds about 65% market share. By March 2026, the test was embedded in the electronic health records of more than 800 large urology practices, cutting ordering friction for physicians.\u003c\/p\u003e\n\u003cp\u003eThat reach matters: it puts genomic risk data in the first consult for about 250,000 patients a year, helping make Decipher the default choice in high-risk pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOptimizing the Afirma thyroid workflow to capture 30 percent of fine-needle aspirates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte can deepen Afirma market penetration by making the thyroid workflow easier to adopt in integrated delivery networks. The Afirma genomic sequencing classifier is the core thyroid test, and workflow gains have helped lift clinician use by about 25 percent over two years. With closed-loop triage that can avoid surgery in roughly 75 percent of indeterminate nodules, Veracyte has a clear path to push biopsy share toward 30 percent through hospital-system volume pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreasing lung cancer diagnostic volume via the Percepta GSC platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's Percepta GSC drives market penetration by helping resolve ambiguous lung nodule cases, which makes it easier for pulmonologists to choose it in routine care. By March 2026, the assay had 95% Medicare coverage, lowering reimbursement friction in community hospitals.\u003c\/p\u003e\n\u003cp\u003eThat support has helped testing volume rise 12% year over year among pulmonologists serving about 1.5 million annual lung scans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeveraging digital pathology tools to enhance the value of Decipher bladder tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte's bladder market penetration pairs Decipher genomic testing with AI-driven digital pathology, giving specialists a fuller risk view before aggressive surgery. The company sells this integrated package to more than 400 cancer centers, which helps it reach the clinics most likely to adopt it first. In specialized clinics, this model has driven a 20% higher adoption rate than standard molecular-only rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding Envisia usage for interstitial lung disease within top 100 respiratory centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVeracyte is pushing Envisia into the 100 leading U.S. respiratory excellence centers, which widens access to a test built for hard-to-diagnose interstitial lung disease. Its own clinical data show 68% of Envisia patients can avoid surgical lung biopsy, a painful and costly step that helps lock in repeat use at major centers.\u003c\/p\u003e\n\u003cp\u003eThat makes Envisia a strong penetration play in Veracyte's 2025 mix: high clinical value, sticky site-level adoption, and a clear high-margin niche in ILD workups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte's Tests Are Winning Default Status in Specialty Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's market penetration play is to make its tests the default in key specialty workflows. Decipher Prostate is in more than 800 urology practices and reaches about 250,000 patients a year, while Afirma and Percepta GSC keep expanding use through easier adoption and payer support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTest\u003c\/th\u003e\n\u003cth\u003ePenetration signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecipher Prostate\u003c\/td\u003e\n\u003ctd\u003e65% share; 800+ practices\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma\u003c\/td\u003e\n\u003ctd\u003e25% use lift in 2 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePercepta GSC\u003c\/td\u003e\n\u003ctd\u003e95% Medicare coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nOutlines Veracyte's growth options across existing and new products and markets\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nProvides a clear Veracyte Ansoff Matrix snapshot to quickly ease growth-strategy uncertainty.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeploying the nCounter flex platform to 35 international healthcare systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy March 2026, Veracyte had extended the nCounter Flex kit model into 35 European and Asian healthcare systems, shifting from a US-centred lab service to local testing. That move lets hospital labs run advanced genomic assays in-house, so Veracyte can scale its IP without funding overseas central labs. In Ansoff terms, this is market development: the same assay platform, sold into 35 new national lab markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eObtaining CE-IVDR certification to enter 15 new European jurisdictions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCE-IVDR certification let Veracyte enter 15 new European jurisdictions and move the Decipher portfolio into harder-to-access markets such as France, Germany, and the United Kingdom. By March 2026, Veracyte had onboarded 20 major European hospitals as anchor tenants for its urology diagnostic suite. Those regions now drive 18% of total international revenue, versus single digits four years earlier.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablishing strategic partnerships for lung cancer screening in Southeast Asia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's Southeast Asia partnerships fit market development: the region still carries a heavy lung-cancer load, with Asia accounting for about 60% of new cases worldwide. By early 2026, local distributor ventures had localized Percepta and reached 50+ hospitals, serving a 5 million-patient annual screening pool.\u003c\/p\u003e\n\u003cp\u003eThat footprint opens a steadier revenue stream outside the volatile US reimbursement cycle. It also widens access in a high-smoking region, where earlier detection can matter most.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaling Immunoscore across global oncology research networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVia the HalioDx legacy, Veracyte has placed Immunoscore in academic centers across 40+ countries, using research demand to expand beyond its home markets. The platform gives oncology teams a common readout for immune response in solid tumors, so it becomes a baseline tool for immunotherapy studies. That broad lab footprint can also smooth later clinical uptake, since researchers and clinicians already know the assay and its performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccessing the Latin American diagnostic market via telehealth diagnostic portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte is using telehealth diagnostic portals to enter Brazil and Mexico by working with private insurers and sending biopsy data and test orders to U.S. labs. This model bypasses weak local infrastructure and has already routed 5,000 high-value international cases to Veracyte, showing demand for American diagnostic precision. In Ansoff terms, it is market development: the same tests, sold into new geographies through digital access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte's global rollout drives 18% international revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's market development strategy centers on exporting the same assay platform into new geographies, not changing the product. By March 2026, its footprint had reached 35 European and Asian healthcare systems, 15 new European jurisdictions, and 20 major European hospitals, with international revenue at 18%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSystems\u003c\/td\u003e\n\u003ctd\u003e35\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational revenue\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eVeracyte Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the actual Veracyte Ansoff Matrix Analysis document you'll receive after purchase-no sample, no placeholder. The content below is taken directly from the full report, so you can review the real structure and quality upfront. Once purchased, the complete version is unlocked for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercializing the Percepta Nasal Swab for early lung cancer detection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's Percepta Nasal Swab moves product development into low-friction lung cancer triage for smokers with lung nodules, cutting the need for immediate invasive workups. By March 2026, it is used in more than 1,200 clinics to help rule out cancer before costly CT follow-up or surgery, supporting faster care decisions. That widens Veracyte's reach into a roughly $30 billion addressable market and expands its non-invasive diagnostics platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaunching a unified urologic portal for multi-cancer diagnostic monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's unified urologic portal links prostate, bladder, and kidney cancer genomic results in one SaaS workflow for 500 urology practices.\u003c\/p\u003e\n\u003cp\u003eBy cutting about 5 staff hours a week per practice, it lowers admin load and speeds result review, which is a clear product-development move in the Ansoff Matrix.\u003c\/p\u003e\n\u003cp\u003eThis shifts Veracyte from a test seller to a workflow partner, deepening retention and raising switching costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrating spatial transcriptomics into the Decipher test menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn Veracyte's Ansoff Matrix, this is product development: the Company can sell more insight from the same Decipher brand by adding spatial transcriptomics. The upgrade adds 500 genomic markers that standard sequencing can miss, which should sharpen risk calls on prostate tumor aggressiveness. A 10% higher average selling price per test also lifts revenue per order without needing a new customer base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRefining MRD monitoring assays for post-treatment surveillance in urology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn Veracyte's Product Development move, the Company is refining MRD monitoring assays for post-treatment bladder cancer surveillance. Its liquid biopsy test reads tumor DNA in urine with 98% sensitivity, so recurrence can be flagged before imaging sees it. By extending testing from diagnosis into 5-year follow-up, Veracyte deepens use per patient and lifts lifecycle value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntroducing a revamped Afirma portal with AI-powered pathology overlays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn Veracyte's Ansoff Matrix, this is product development: the Afirma thyroid classifier now pairs genomic data with AI-assisted cytopathology overlays that read cell shape and pattern. Veracyte says the latest version lifts diagnostic specificity by 12% versus the prior release, which helps cut false positives.\u003c\/p\u003e\n\u003cp\u003eThat gain keeps Afirma ahead of low-cost genomic rivals by adding harder-to-copy clinical depth. For investors, the move defends pricing power and supports repeat use in a category that still relies on high-trust pathology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte Deepens Clinical Reach With New Test Enhancements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's product development adds new clinical layers to its existing tests: Percepta Nasal Swab now supports over 1,200 clinics, the urology portal serves 500 practices, and Decipher's spatial upgrade adds 500 genomic markers. These moves raise use per patient and strengthen retention.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePercepta\u003c\/td\u003e\n\u003ctd\u003e1,200+ clinics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrology portal\u003c\/td\u003e\n\u003ctd\u003e500 practices\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding bio-pharma services for clinical trial patient stratification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte has diversified beyond diagnostics by selling high-resolution genomic insights to pharmaceutical companies for clinical trial patient stratification. By March 2026, it was supporting over 45 active trials, helping sponsors pick the patient subgroups most likely to respond to new immunotherapies. This service line generated about 15% of annual revenue and helped cushion swings in diagnostic volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePivoting into companion diagnostics for next-generation solid tumor therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Veracyte is widening beyond biopsy testing by co-developing companion diagnostics with 3 of the world's top 10 pharmaceutical firms for orphan solid-tumor drugs. Once FDA approval lands, the test becomes part of the drug label, so revenue can scale with each prescription, not just with one-time sample volume. That shifts the mix toward longer-lived, recurring income and ties growth to drug sales in a market where more than 1.9 million new U.S. cancer cases were expected in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApplying genomic insights to the metabolic liver disease screening market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUsing its sequencing base, Veracyte is moving from oncology into MASH screening, a market tied to a much larger metabolic disease pool. Its research-grade assay showed about 90% correlation with liver biopsy in early trials, which matters because biopsy is invasive and limits testing scale. If the result holds in larger 2025 studies, this could open a far bigger addressable market than its core cancer tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvesting in spatial biology research-use-only kits for global scientists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte has diversified into RUO spatial biology by selling standardized HalioDx-based kits to global researchers. These kits let university and government labs run high-end spatial profiling on their own schedule with 100-marker panels, so Veracyte earns revenue at the start of the innovation pipeline, before clinical adoption. That broadens the Company Name's exposure beyond diagnostics and lowers reliance on late-stage tests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaunching an AI-driven predictive modeling service for immuno-oncology response\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte's AI-driven predictive modeling for immuno-oncology response is a diversification move: it uses about 200,000 registry data points to give physicians 5-year survival probabilities, shifting the firm from lab testing into digital health. That creates a separate, data-led revenue stream that can scale without matching test volume one-for-one.\u003c\/p\u003e\n\u003cp\u003eFor Veracyte, this lowers reliance on physical assays and adds higher-margin software-style economics, which can matter as oncology care keeps moving toward evidence-based treatment selection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte's pharma expansion is driving durable, scalable growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's diversification extends the Company Name beyond core diagnostics into pharma services, RUO spatial biology, and companion diagnostics, reducing dependence on one-off test volume. By March 2026, it was supporting 45+ active trials, with this line contributing about 15% of annual revenue.\u003c\/p\u003e\n\u003cp\u003eIts MASH and AI-based programs widen the addressable market and can scale with drug use, not just sample counts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025-2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma trials\u003c\/td\u003e\n\u003ctd\u003e45+ active trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue mix\u003c\/td\u003e\n\u003ctd\u003e~15% of annual revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMASH assay\u003c\/td\u003e\n\u003ctd\u003e~90% biopsy correlation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SWOT Analysis Template","offers":[{"title":"Default Title","offer_id":57340574171518,"sku":"veracyte-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/9204\/3902\/files\/veracyte-ansoff-analysis.webp?v=1777716126","url":"https:\/\/swot-analysis-template.com\/products\/veracyte-ansoff-matrix","provider":"SWOT Analysis Template","version":"1.0","type":"link"}